JO Volume 6 - HIV - Clinical Care Options

Timing of initiation of antiretroviral drugs during tuberculosis therapy.

Authors: Abdool Karim SS, Naidoo K, Grobler A, et al.

Citation: N Engl J Med. 2010;362:697-706.

Source: Journal Options for HIV - Volume 6

Date Posted: 6/1/2010

Capsule Summary | Expert Commentary | Slideset | Abstract
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Authors: Cooper DA, Heera J, Goodrich J, et al.

Citation: J Infect Dis. 2010;201:803-813.

Source: Journal Options for HIV - Volume 6

Date Posted: 6/1/2010

Capsule Summary | Expert Commentary | Slideset | Abstract
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

Authors: Eron JJ, Young B, Cooper DA, et al.

Citation: Lancet. 2010;375:396-407.

Source: Journal Options for HIV - Volume 6

Date Posted: 6/1/2010

Capsule Summary | Expert Commentary | Slideset | Abstract
Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.

Authors: Hatano H, Lampiris H, Fransen S, et al.

Citation: J Acquir Immune Defic Syndr. 2010;[Epub ahead of print].

Source: Journal Options for HIV - Volume 6

Date Posted: 6/1/2010

Capsule Summary | Expert Commentary | Slideset | Abstract
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Authors: Lingappa JR, Baeten JM, Wald A, et al.

Citation: Lancet. 2010;375:824-833.

Source: Journal Options for HIV - Volume 6

Date Posted: 6/1/2010

Capsule Summary | Expert Commentary | Slideset | Abstract
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients.

Authors: Mueller NJ, Fux CA, Ledergerber B, et al.

Citation: AIDS. 2010;24:1127-1134.

Source: Journal Options for HIV - Volume 6

Date Posted: 6/1/2010

Capsule Summary | Expert Commentary | Slideset | Abstract
Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.

Authors: Wever K, van Agtmael MA, Carr A.

Citation: J Acquir Immune Defic Syndr. 2010;[Epub ahead of print].

Source: Journal Options for HIV - Volume 6

Date Posted: 6/1/2010

Capsule Summary | Expert Commentary | Slideset | Abstract
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.

Authors: Winston A, Duncombe C, Li PC, et al.

Citation: Clin Infect Dis. 2010;50:920-929.

Source: Journal Options for HIV - Volume 6

Date Posted: 6/1/2010

Capsule Summary | Expert Commentary | Slideset | Abstract

Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.

Other Sites

Topics

Educational Formats

Program Resources

User Resources

PDF
Video

Help
Site Tour
RSS

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Journal Options for HIV - Volume 6 Source: Journal Options for HIV - Volume 6
Table of Contents Issue 1 Collection • Issue 1 Collection Articles	Latest Content 8 of 8 Shown Timing of initiation of antiretroviral drugs during tuberculosis therapy. Authors: Abdool Karim SS, Naidoo K, Grobler A, et al. Citation: N Engl J Med. 2010;362:697-706. Source: Journal Options for HIV - Volume 6 Date Posted: 6/1/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. Authors: Cooper DA, Heera J, Goodrich J, et al. Citation: J Infect Dis. 2010;201:803-813. Source: Journal Options for HIV - Volume 6 Date Posted: 6/1/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Authors: Eron JJ, Young B, Cooper DA, et al. Citation: Lancet. 2010;375:396-407. Source: Journal Options for HIV - Volume 6 Date Posted: 6/1/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. Authors: Hatano H, Lampiris H, Fransen S, et al. Citation: J Acquir Immune Defic Syndr. 2010;[Epub ahead of print]. Source: Journal Options for HIV - Volume 6 Date Posted: 6/1/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Authors: Lingappa JR, Baeten JM, Wald A, et al. Citation: Lancet. 2010;375:824-833. Source: Journal Options for HIV - Volume 6 Date Posted: 6/1/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. Authors: Mueller NJ, Fux CA, Ledergerber B, et al. Citation: AIDS. 2010;24:1127-1134. Source: Journal Options for HIV - Volume 6 Date Posted: 6/1/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. Authors: Wever K, van Agtmael MA, Carr A. Citation: J Acquir Immune Defic Syndr. 2010;[Epub ahead of print]. Source: Journal Options for HIV - Volume 6 Date Posted: 6/1/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Authors: Winston A, Duncombe C, Li PC, et al. Citation: Clin Infect Dis. 2010;50:920-929. Source: Journal Options for HIV - Volume 6 Date Posted: 6/1/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract 8 of 8 Shown Show 0 More Loading...	Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. Contact Info Educational grant provided by: Educational grants support only the CME-certified components of this program.

Source: Journal Options for HIV - Volume 6

Table of Contents

Latest Content